Vaccine waivers alone can’t solve India’s vaccine crisis
It’s a strange predicament for one of the largest providers of vaccines in the world, a nation that was preferably positioned to quickly ramp up vaccine manufacturing. India scored a little victory on May 5th, when the United States revealed its support for an intellectual property rights waiver on vaccines and agreed to get involved in its settlements. Waiving intellectual property rights could offer vaccine manufacturers the details they need to ramp up vaccine production so that more individuals in the world get their jabs. While it might be possible for India to bypass the intellectual home rights, basically bypassing the pharma companies and approving other factories authorization to produce vaccines, it is not likely to do so. “It takes a significant quantity of time, a couple of months, for vaccine manufacturers to put in location facilities, raw products, skilled workers and plans with vendors to begin making the vaccines,”stated Shivangi Mittal, senior associate at Koan Advisory Group, a technology policy consulting company.
It’s a bizarre circumstance for one of the biggest suppliers of vaccines in the world, a country that was preferably positioned to rapidly ramp up vaccine manufacturing. Waiving intellectual property rights might give vaccine makers the info they need to ramp up vaccine production so that more people in the world get their jabs. “It takes a considerable amount of time, a couple of months, for vaccine producers to put in location infrastructure, raw materials, knowledgeable workers and arrangements with suppliers to start making the vaccines,”said Shivangi Mittal, senior associate at Koan Advisory Group, an innovation policy consulting firm.